Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Intra-Cellular Therapies, Inc is a biotechnology business based in the US. Intra-Cellular Therapies shares (ITCI) are listed on the NASDAQ and all prices are listed in US Dollars. Intra-Cellular Therapies employs 330 staff and has a trailing 12-month revenue of around USD$3.1 million.
|52-week range||USD$8.27 - USD$43.56|
|50-day moving average||USD$25.9766|
|200-day moving average||USD$21.9889|
|Wall St. target price||USD$54.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.814|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$3.1 million|
|Gross profit TTM||USD$-89,064,225|
|Return on assets TTM||-31.98%|
|Return on equity TTM||-58.64%|
|Market capitalisation||USD$2.1 billion|
TTM: trailing 12 months
There are currently 5.9 million Intra-Cellular Therapies shares held short by investors – that's known as Intra-Cellular Therapies's "short interest". This figure is 12.9% down from 6.7 million last month.
There are a few different ways that this level of interest in shorting Intra-Cellular Therapies shares can be evaluated.
Intra-Cellular Therapies's "short interest ratio" (SIR) is the quantity of Intra-Cellular Therapies shares currently shorted divided by the average quantity of Intra-Cellular Therapies shares traded daily (recently around 4.1 million). Intra-Cellular Therapies's SIR currently stands at 1.44. In other words for every 100,000 Intra-Cellular Therapies shares traded daily on the market, roughly 1440 shares are currently held short.
However Intra-Cellular Therapies's short interest can also be evaluated against the total number of Intra-Cellular Therapies shares, or, against the total number of tradable Intra-Cellular Therapies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Intra-Cellular Therapies's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Intra-Cellular Therapies shares in existence, roughly 70 shares are currently held short) or 0.0835% of the tradable shares (for every 100,000 tradable Intra-Cellular Therapies shares, roughly 84 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Intra-Cellular Therapies.
Find out more about how you can short Intra-Cellular Therapies stock.
We're not expecting Intra-Cellular Therapies to pay a dividend over the next 12 months.
Over the last 12 months, Intra-Cellular Therapies's shares have ranged in value from as little as $8.27 up to $43.56. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Intra-Cellular Therapies's is 1.6387. This would suggest that Intra-Cellular Therapies's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company is developing its lead drug candidate, CAPLYTA for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases. It is also developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for Parkinson's disease; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.